WO2024017485A1 - Composition based on dry extract of red cinchona, and the antiasthenic and antiviral effect thereof - Google Patents
Composition based on dry extract of red cinchona, and the antiasthenic and antiviral effect thereof Download PDFInfo
- Publication number
- WO2024017485A1 WO2024017485A1 PCT/EP2022/073828 EP2022073828W WO2024017485A1 WO 2024017485 A1 WO2024017485 A1 WO 2024017485A1 EP 2022073828 W EP2022073828 W EP 2022073828W WO 2024017485 A1 WO2024017485 A1 WO 2024017485A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- content
- composition
- mass
- dry extract
- optionally
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 title claims abstract description 19
- 235000006768 Cinchona succirubra Nutrition 0.000 title claims abstract description 7
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 6
- 241000489438 Cinchona pubescens Species 0.000 title 1
- 239000006188 syrup Substances 0.000 claims abstract description 14
- 235000020357 syrup Nutrition 0.000 claims abstract description 11
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 8
- 240000000011 Artemisia annua Species 0.000 claims abstract description 8
- 241001632410 Eleutherococcus senticosus Species 0.000 claims abstract description 8
- 244000182633 Cinchona succirubra Species 0.000 claims abstract description 6
- 230000003612 virological effect Effects 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000009160 phytotherapy Methods 0.000 claims abstract 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 8
- 235000009566 rice Nutrition 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000001268 cinchona succirubra pav. Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 206010003549 asthenia Diseases 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000209094 Oryza Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940107147 siberian ginseng root Drugs 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Definitions
- the object of the invention relates to a liquid composition, formulated for oral administration, based on dry plant extracts.
- composition is intended for use in herbal medicine, to obtain a physiological effect on the body, in particular antiviral as well as an anti-asthenic effect post viral and/or bacterial infection.
- composition called ARTEMIPERKYNINE-syrup, is formulated as a syrup for oral administration.
- the syrup chosen is a rice syrup.
- composition further comprising active ingredients, excipients, water and an alcohol.
- the dry extract of Red Cinchona bark is prepared after harvesting the bark of the shrubs, which will be cut into pieces, dried, then crushed to obtain a dry extract.
- the dry extract of Artemisia annua is prepared after harvesting the leaves and fine stems of the plant, which will be dried, then crushed to obtain a dry extract.
- the dry extract of Siberian Ginseng root is prepared after harvesting the roots of Siberian Ginseng, which will be cut into thin strips, dried, pasteurized, then crushed to obtain a dry extract.
- the 60° alcohol will be incorporated at a rate of 10% of the total weight by mass, and the Sodium Benzoate may be optionally added to the hydroalcoholic solution thus obtained, at a rate of 0 to 0, 15% of the total weight of the composition.
- a lemon flavor can be added optionally, after the addition of the dry extracts, in a proportion of 0 to 1% of the total weight of the composition.
- the solution is filtered in order to eliminate any unsolubilized residue, in order to eliminate particles greater than 400 pm. This filtration is carried out using a suitable sieve.
- Rice syrup is obtained by fermenting brown rice. During enzymatic fermentation, rice is transformed into half complex sugars and half simple sugars.
- the mixture obtained and filtered is concentrated by evaporation of the water, until a rice syrup is obtained.
- the rice syrup is incorporated into the aqueous solution at a temperature of 40°C.
- citric acid is optionally added, at a rate of 0 to 0.8% total weight, in order to maintain a pH between 3 and 5.
- This composition concerns the antiasthenic and antibacterial effect of Red Cinchona.
- the antiviral properties of Artemisia annua and immunostimulating properties of Siberian Ginseng potentiate the action of Red Cinchona, and are likely to accelerate the healing process and prevent viral and/or bacterial relapses.
- composition is indicated in the treatment of post-infectious viral and/or bacterial asthenia, in convalescent people.
Abstract
The invention relates to a liquid composition, in syrup form, for oral administration, based on dry extract from plants: red cinchona, and optionally Artemisia annua and Siberian ginseng, and also to the method for producing same. The composition is intended for use in phytotherapy, in order to obtain an antiviral and antiasthenic effect in viral and/or bacterial infections.
Description
ARTEMIPERKYNINE-sirop ARTEMIPERKYNINE-syrup
Description : Description :
COMPOSITION À BASE D'EXTRAIT SEC DE QUINQUINA ROUGE ET SON EFFET ANTIASTHÉNIQUE ET ANTIVIRAL COMPOSITION BASED ON DRY EXTRACT OF RED CINQUINA AND ITS ANTIASTHENIC AND ANTIVIRAL EFFECT
L’objet de l’invention concerne une composition liquide, formulée pour une administration orale, à base d’extraits secs de plantes. The object of the invention relates to a liquid composition, formulated for oral administration, based on dry plant extracts.
La composition est destinée à une utilisation en phytothérapie, pour l’obtention d’un effet physiologique sur l’organisme, en particulier antiviral ainsi qu’un effet anti asthénique post infection virale et/ou bactérienne The composition is intended for use in herbal medicine, to obtain a physiological effect on the body, in particular antiviral as well as an anti-asthenic effect post viral and/or bacterial infection.
La composition, appelée ARTEMIPERKYNINE-sirop, est formulée sous forme d’un sirop pour une administration orale. The composition, called ARTEMIPERKYNINE-syrup, is formulated as a syrup for oral administration.
Le sirop choisi est un sirop de riz. The syrup chosen is a rice syrup.
La dite composition comprenant en outre des principes actifs, des excipients, de l’eau et un alcool. Said composition further comprising active ingredients, excipients, water and an alcohol.
DESCRIPTION DETAILLEE DE L’INVENTION : DETAILED DESCRIPTION OF THE INVENTION:
Etape a de la préparation hydroalcoolique d’extrait sec de Quinquina rouge, d Artemisia Annua et du Ginseng de Sibérie, Step a of the hydroalcoholic preparation of dry extract of Red Cinchona, Artemisia Annua and Siberian Ginseng,
L’extrait sec d’écorce de Quinquina rouge, est préparé après récolte de l’écorce des arbustes, qui sera découpée en morceaux, séchée, puis broyée pour obtenir un extrait sec. The dry extract of Red Cinchona bark is prepared after harvesting the bark of the shrubs, which will be cut into pieces, dried, then crushed to obtain a dry extract.
L’extrait sec d’ Artemisia annua est préparé après récolte des feuilles et des tiges fines de la plante, qui seront séchées, puis broyées pour obtenir un extrait sec. The dry extract of Artemisia annua is prepared after harvesting the leaves and fine stems of the plant, which will be dried, then crushed to obtain a dry extract.
L’extrait sec de racine de Ginseng de Sibérie est préparé après récolte des racines de Ginseng de Sibérie, qui seront découpées en fines lamelles, séchées, pasteurisées, puis broyées pour obtenir un extrait sec. The dry extract of Siberian Ginseng root is prepared after harvesting the roots of Siberian Ginseng, which will be cut into thin strips, dried, pasteurized, then crushed to obtain a dry extract.
Ces extraits secs seront progressivement introduits dans les proportions suivantes : These dry extracts will be gradually introduced in the following proportions:
9,5 % à 19 % en masse d’écorce de Quinquina rouge 9.5% to 19% by mass of red Cinchona bark
0 à 9,5 % de feuilles et tiges d’ Artemisia Annua 0 to 9.5% leaves and stems of Artemisia Annua
0 à 1 % en masse de Ginseng de Sibérie 0 to 1% by mass of Siberian Ginseng
Ces extraits secs seront introduits dans une solution constituée entre 43,05 à 46% d’eau en poids total de la composition.
Cette incorporation sera réalisée à 80°. La solution est maintenue sous agitation mécanique pendant 90 minutes. These dry extracts will be introduced into a solution consisting of between 43.05 to 46% water by total weight of the composition. This incorporation will be carried out at 80°. The solution is kept under mechanical stirring for 90 minutes.
Pendant cette étape a, après refroidissement, l’alcool à 60° sera incorporé à raison de 10 % du poids total en masse, et le Benzoate de Sodium pourra être additionné optionnellement à la solution hydroalcoolique ainsi obtenue, à raison de 0 à 0,15 % du poids total de la composition. During this step a, after cooling, the 60° alcohol will be incorporated at a rate of 10% of the total weight by mass, and the Sodium Benzoate may be optionally added to the hydroalcoholic solution thus obtained, at a rate of 0 to 0, 15% of the total weight of the composition.
Au cours de cette étape un arôme citron pourra être ajouté optionnellement, après l’addition des extraits secs, en proportion de 0 à 1% du poids total de la composition. During this step, a lemon flavor can be added optionally, after the addition of the dry extracts, in a proportion of 0 to 1% of the total weight of the composition.
Etape b de filtration Filtration step b
A l’issue de l’étape a, la solution est fdtrée afin d’éliminer tout résidu non solubilisé, afin d’éliminer les particules supérieures à 400pm. Cette filtration est réalisée au moyen d’un tamis approprié.At the end of step a, the solution is filtered in order to eliminate any unsolubilized residue, in order to eliminate particles greater than 400 pm. This filtration is carried out using a suitable sieve.
Etape c d’incorporation du sirop de riz Step c of incorporating the rice syrup
Le sirop de riz est obtenu par la fermentation de riz brun. Au cours de la fermentation enzymatique, le riz est transformé pour moitié en sucres complexes et en sucres simples. Rice syrup is obtained by fermenting brown rice. During enzymatic fermentation, rice is transformed into half complex sugars and half simple sugars.
Le mélange obtenu et filtré est concentré par évaporation de l’eau, jusqu’à obtention d’un sirop de riz. The mixture obtained and filtered is concentrated by evaporation of the water, until a rice syrup is obtained.
Le sirop de riz est incorporé à la solution aqueuse à une température située à 40°C. The rice syrup is incorporated into the aqueous solution at a temperature of 40°C.
Au cours de l’étape c, on rajoute optionnellement l’Acide citrique, à raison de 0 à 0,8 % poids total, afin de maintenir un ph entre 3 et 5. During step c, citric acid is optionally added, at a rate of 0 to 0.8% total weight, in order to maintain a pH between 3 and 5.
Etape d’homogénéisation d Homogenization step d
Au cours de cette étape, la solution ainsi obtenue sera agitée mécaniquement pendant 30 minutes à température ambiante. During this step, the solution thus obtained will be mechanically stirred for 30 minutes at room temperature.
Toutes ces étapes seront réalisées dans des cuves en acier inoxydables, fermées, et pouvant être agitées mécaniquement. All these steps will be carried out in closed stainless steel tanks which can be mechanically stirred.
Le mécanisme d’action de cette composition concerne l’effet antiasthénique et antibactérien du Quinquina rouge. Les propriétés antivirales de I’ Artemisia annua et immunostimulantes du Ginseng de Sibérie potentialisent l’action du Quinquina rouge, et sont susceptibles d’accélérer le processus de guérison et de prévenir les rechutes virales et/ou bactériennes. The mechanism of action of this composition concerns the antiasthenic and antibacterial effect of Red Cinchona. The antiviral properties of Artemisia annua and immunostimulating properties of Siberian Ginseng potentiate the action of Red Cinchona, and are likely to accelerate the healing process and prevent viral and/or bacterial relapses.
La composition est indiquée dans le traitement de l’asthénie post infectieuse virale et/ou bactérienne, chez les personnes en convalescence. The composition is indicated in the treatment of post-infectious viral and/or bacterial asthenia, in convalescent people.
Tableau de la composition de l’ARTEMIPERKYNINE- sirop
[Tableau 1]
Table of composition of ARTEMIPERKYNINE- syrup [Table 1]
Claims
[Revendication 1] Composition liquide sous une forme adaptée pour une administration orale à base d’extraits secs Quinquina rouge, et optionnellement d’Artemisia annua et de Ginseng de Sibérie comprenant par rapport à la masse totale de la composition : [Claim 1] Liquid composition in a form suitable for oral administration based on dried extracts of Red Cinchona, and optionally of Artemisia annua and Siberian Ginseng comprising in relation to the total mass of the composition:
• Un sirop de riz en une teneur de 25 % de pourcentage massique • A rice syrup with a content of 25% by mass percentage
• Des extraits secs : de Quinquina rouge en une teneur de 9,5 % à 19 % de pourcentage massique. Artemisia annua en une teneur de 0 à 9,5 % de pourcentage massique, de Ginseng de Sibérie en une teneur de 0 à 1 % de pourcentage massique. • Dry extracts: of red Cinchona in a content of 9.5% to 19% by weight. Artemisia annua in a content of 0 to 9.5% by mass percentage, Siberian Ginseng in a content of 0 to 1% by mass percentage.
• De l’eau en une teneur de 43,05 à 46 % de pourcentage massique • Water in a content of 43.05 to 46% mass percentage
• Du Benzoate de Sodium en une teneur de 0 à 0,15 % de pourcentage massique • Sodium Benzoate in a content of 0 to 0.15% by mass
• De l’alcool à 60° en une teneur de 10 % de pourcentage massique• Alcohol at 60° in a content of 10% by mass
• De l’ Acide citrique en une teneur de 0 à 0,8 % de pourcentage massique• Citric acid in a content of 0 to 0.8% by mass
• Optionnellement un arôme citron en une teneur de 0 à 1% de pourcentage massique. • Optionally a lemon flavor in a content of 0 to 1% mass percentage.
[Revendication 2] Procédé de préparation d’une composition selon la revendication 1, comprenant les étapes suivantes : [Claim 2] Process for preparing a composition according to claim 1, comprising the following steps:
(a) Une étape de préparation de la solution aqueuse dans laquelle on fait infuser dans de l’eau purifiée, l’extrait sec d’ écorce de Quinquina rouge, broyée, et optionnellement l’extrait sec de tiges et de feuilles broyées (T Artemisia annua et l’extrait sec de Ginseng de Sibérie broyé, à une température de 80 °C, dans les mêmes proportions que selon la revendication 1, dans laquelle on ajoute après refroidissement, l’alcool, et optionnellement l’agent conservateur Benzoate de Sodium, puis un arôme citron après l’addition des extraits secs, en proportion de 0 à 1% du poids total de la composition ; (a) A step of preparing the aqueous solution in which the dry extract of crushed Red Cinchona bark is infused in purified water, and optionally the dry extract of crushed stems and leaves (T Artemisia annua and the dry extract of crushed Siberian Ginseng, at a temperature of 80 °C, in the same proportions as according to claim 1, in which after cooling, the alcohol, and optionally the preservative agent Benzoate of Sodium, then a lemon flavor after the addition of the dry extracts, in a proportion of 0 to 1% of the total weight of the composition;
(b) Une étape de filtration de la solution aqueuse obtenue à l’étape a. (b) A step of filtration of the aqueous solution obtained in step a.
(c) Une étape d’incorporation sous agitation à la solution aqueuse obtenue à l’étape b, du sirop de riz à une température de 40 °C ; (c) A step of incorporating, with stirring, rice syrup into the aqueous solution obtained in step b at a temperature of 40°C;
(d) Une étape d’homogénéisation de la composition obtenue à l’étape c. (d) A step of homogenization of the composition obtained in step c.
[Revendication 3] Composition selon l’une des revendications 1 ou 2, pour son utilisation comme phytothérapie antivirale et dans le traitement de l’asthénie post infectieuse virale et/ou bactérienne
[Claim 3] Composition according to one of claims 1 or 2, for its use as antiviral phytotherapy and in the treatment of post-infectious viral and/or bacterial asthenia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/070109 WO2024017459A1 (en) | 2022-07-18 | 2022-07-18 | Composition based on dry extract of artemisia annua plant and siberian ginseng root |
| EPPCT/EP2022/070109 | 2022-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024017485A1 true WO2024017485A1 (en) | 2024-01-25 |
Family
ID=83050092
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/070109 WO2024017459A1 (en) | 2022-07-18 | 2022-07-18 | Composition based on dry extract of artemisia annua plant and siberian ginseng root |
| PCT/EP2022/073828 WO2024017485A1 (en) | 2022-07-18 | 2022-08-26 | Composition based on dry extract of red cinchona, and the antiasthenic and antiviral effect thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/070109 WO2024017459A1 (en) | 2022-07-18 | 2022-07-18 | Composition based on dry extract of artemisia annua plant and siberian ginseng root |
Country Status (1)
| Country | Link |
|---|---|
| WO (2) | WO2024017459A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009051803A (en) * | 2007-08-28 | 2009-03-12 | Yoshiaki Nagaura | Discovery of new method for extraction |
| US8637094B2 (en) * | 2007-07-18 | 2014-01-28 | Iraj E. Kiani | Composition and method for treating viral conditions |
| FR3109084A1 (en) * | 2020-04-08 | 2021-10-15 | Vanessa PANTEGHINI | PERKYNINE, phytotherapeutic composition with antiasthenic effect |
| FR3110837A1 (en) * | 2020-06-02 | 2021-12-03 | Vanessa PANTEGHINI | Syrup based on Artemisia annua, ARTEMIPREV |
-
2022
- 2022-07-18 WO PCT/EP2022/070109 patent/WO2024017459A1/en unknown
- 2022-08-26 WO PCT/EP2022/073828 patent/WO2024017485A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637094B2 (en) * | 2007-07-18 | 2014-01-28 | Iraj E. Kiani | Composition and method for treating viral conditions |
| JP2009051803A (en) * | 2007-08-28 | 2009-03-12 | Yoshiaki Nagaura | Discovery of new method for extraction |
| FR3109084A1 (en) * | 2020-04-08 | 2021-10-15 | Vanessa PANTEGHINI | PERKYNINE, phytotherapeutic composition with antiasthenic effect |
| FR3110837A1 (en) * | 2020-06-02 | 2021-12-03 | Vanessa PANTEGHINI | Syrup based on Artemisia annua, ARTEMIPREV |
Non-Patent Citations (2)
| Title |
|---|
| ANONYMOUS: "Top 13 Benefits of Eleuthero Root (Siberian Ginseng)", INTERNET CITATION, 27 July 2017 (2017-07-27), pages 1 - 7, XP002777749, Retrieved from the Internet <URL:https://web.archive.org/web/20170727160053/http://urbol.com/siberian-eleuthero-ginseng/> * |
| RAZA MUHAMMAD ADNAN ET AL: "THE MEDICINAL AND AROMATIC ACTIVITIES OF CINCHONA: A REVIEW", ASIAN JOURNAL OF ADVANCES IN RESEARCH, 4 June 2021 (2021-06-04), pages 42 - 45, XP093031599, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Fazal-Ur-Rehman-2/publication/352125307_The_Medicinal_and_Aromatic_Activities_of_Cinchona_A_Review/links/60ba2490299bf10dff96d008/The-Medicinal-and-Aromatic-Activities-of-Cinchona-A-Review.pdf> [retrieved on 20230314] * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024017459A1 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0282002B1 (en) | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care | |
| JPWO2005072684A1 (en) | Maca extract manufacturing method | |
| TW201825082A (en) | Hair restoration/growth stimulating agent | |
| FR2695561A1 (en) | Cosmetic or dermatological composition containing at least one saponin of ginsenoside type, and its applications, in particular for hair care. | |
| FR2669225A1 (en) | USE OF MEDICAGO SAPONINS FOR THE PREPARATION OF COSMETIC OR PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR DERMATOLOGICAL. | |
| JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
| WO2012108104A1 (en) | Hair growth agent / hair tonic | |
| WO2024017485A1 (en) | Composition based on dry extract of red cinchona, and the antiasthenic and antiviral effect thereof | |
| EP2376094A1 (en) | Cactus fruit extract | |
| FR3109084A1 (en) | PERKYNINE, phytotherapeutic composition with antiasthenic effect | |
| EP0224550B1 (en) | Cosmetic compositions having skin calming and skin regenerating effect and process for the preparation thereof | |
| JP3297673B2 (en) | Composition for lowering blood alcohol concentration containing pepino extract and method for producing the same | |
| JPS5916814A (en) | Composition for oral cavity | |
| WO2013078754A1 (en) | Promoting hair growth solution containing chlorine dioxide， preparation method and use method thereof | |
| EP2329836A1 (en) | Extracts obtained from hoodia gordonii cells lines, their preparation and use | |
| JPS5913716A (en) | Composition for external use | |
| WO2010041703A1 (en) | Anti-sars coronavirus agent, and product containing anti-sars coronavirus agent | |
| TWI384993B (en) | Loquat leaf cell extracts useful for hepatoprotection and/or reducing fat and preparation methods and uses of the same | |
| FR3110837A1 (en) | Syrup based on Artemisia annua, ARTEMIPREV | |
| KR20190057727A (en) | Composition for improving bronchial health improved palatability | |
| RU2234913C1 (en) | Agent "ginseng-2" for bath | |
| FR2940113A1 (en) | CAROB BEAN HYDROLYSAT, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN CAPILLARY COSMETICS | |
| EP2381922B1 (en) | Use of a cometic hair care composition comprising an extract of acanthus | |
| TWI235663B (en) | Oral liquid preparations | |
| JP3382148B2 (en) | External preparation for head |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22777224 Country of ref document: EP Kind code of ref document: A1 |